• LG 101506: Practical RXR Modulator Workflows

  2026-09-29

  Build reproducible RXR signaling assays with LG 101506, from reporter studies to pathway-focused cancer models. This workflow distinguishes direct receptor biology from hypothesis-generating applications in PD-L1 and triple-negative breast cancer research.

• Human iPSC Intestinal Organoids for Pharmacokinetics

  2026-09-29

  The 2025 reference study establishes a direct three-dimensional culture strategy for generating expandable intestinal organoids from human induced pluripotent stem cells. These organoids can be propagated, cryopreserved, and differentiated into intestinal epithelial cells with enterocyte-associated CYP and transporter activities, creating a more human-relevant platform for pharmacokinetic studies.

• Kir2.1 Inhibition in Pulmonary Vascular Remodeling

  2026-09-28

  The reference study identifies KIR2.1 as a regulator of pulmonary artery smooth muscle cell proliferation and migration in pulmonary hypertension models. Using monocrotaline-induced pulmonary hypertension, PDGF-BB-stimulated human cells, ML133, and SB431542, the authors connect KIR2.1 activity with the TGF-β1/SMAD2/3 pathway, OPN, and PCNA expression.

• H 89 2HCl in Trigeminal Pain Pathway Assays

  2026-09-28

  Use H 89 2HCl to test whether PKA contributes to cAMP-linked responses in trigeminal pain models—not as a stand-in for the PKC, calcium, or Piezo2 mechanisms highlighted by recent research. This workflow pairs dose-controlled inhibition with phosphorylation, calcium, and sensory readouts while flagging the concentrations and controls needed to interpret H-89’s broader kinase activity.

• Z-YVAD-FMK: Caspase-1 Inhibitor Evidence

  2026-09-27

  Z-YVAD-FMK is an irreversible, cell-permeable caspase-1 inhibitor used to investigate inflammatory signaling and caspase-1-associated cell death. Product information reports activity in Caco-2 cells and reduced retinal caspase-1 activity in animals, but those findings do not establish a universal dose or prove pyroptosis in every model.

• Hydroxytyrosol in Kidney Injury Research: A Redox Probe

  2026-09-26

  Explore how Hydroxytyrosol can help researchers test redox contributions to nicotine-associated kidney injury without confusing antioxidant effects with receptor blockade. This evidence-aware guide connects kidney disease mechanisms to practical model design and reagent handling.

• ExoU, Lipid Remodeling, and Host Cell Death

  2026-09-25

  A University of Ottawa thesis links ExoU-producing Pseudomonas aeruginosa with reduced host-cell viability and increased lysophosphatidylcholine levels, supporting a role for ExoU-associated membrane hydrolysis. Pharmacological tests did not show a sustained viability rescue from apoptosis or necroptosis inhibition, while early ferroptosis inhibition gave a transient effect, highlighting the need to distinguish lipid damage from downstream cell-death pathways.

• Z-VAD-FMK in Ferroptosis Assay Design

  2026-09-25

  Z-VAD-FMK can help distinguish caspase-dependent apoptosis from ferroptosis—but it should be interpreted as a pathway control, not a ferroptosis inhibitor. This article connects its mechanism to recent TFEB–NRF2 findings in NSCLC and shows how to design more informative cell-death experiments.

• QPRT Drives Breast Cancer Invasion via MLC Phosphorylation

  2026-09-24

  Liu and colleagues link elevated quinolinate phosphoribosyltransferase (QPRT) to breast cancer cell migration and invasion, identifying myosin light chain phosphorylation as a central downstream correlate. Genetic perturbations and inhibitor-based experiments implicate purinergic signaling and Rho–ROCK, PLC, and MLCK pathways, while leaving the precise pathway order and clinical relevance to be tested.

• Dual-Enzyme Peptide Assembly for Cancer Selectivity

  2026-09-24

  A 2026 study reports a zwitterionic peptide amphiphile that responds sequentially to MMP-7 and cathepsin B, shifting from disassembly to fiber-forming assembly in cancer-cell lysosomes. The authors report a cancer selectivity index of 64.1 and tumor regression in an HT-29 xenograft model, while the findings remain preclinical and dependent on the tested enzyme and model contexts.

• LY364947 Workflows for TGF-β and EMT Research

  2026-09-23

  Use LY364947 to test whether TGF-β receptor signaling drives Smad2 activation and EMT-like changes in your model. This practical workflow pairs proximal signaling readouts with phenotype assays, while distinguishing pathway-specific evidence from the broader mechanisms studied in pancreatic cancer.

• H3K18 Lactylation Drives CRC via METTL5–CCT2

  2026-09-23

  The reference study identifies an H3K18 lactylation–METTL5–CCT2 pathway that connects lactate metabolism, epigenetic regulation, m6A RNA modification, and pyroptosis in colorectal cancer. Its findings provide a mechanistic framework for biomarker validation and for testing whether pathway-informed expression assays can support translational studies.

• CAPE at the Stat3–NF-κB Neuroinflammation Interface

  2026-09-22

  Caffeic Acid Phenethyl Ester (CAPE) offers translational researchers a defined chemical probe for separating NF-κB-dependent inflammation from Stat3-linked neurodegenerative signaling. This article connects Fyn-driven zebrafish neurodegeneration with CAPE’s established oncology and NF-κB research profile while emphasizing controls for specificity, exposure, solubility, and cross-model interpretation.

• Protease Inhibitor Cocktail for Plant Protein Workflows

  2026-09-22

  Protect plant lysates from rapid proteolysis while preserving phosphorylated and non-phosphorylated targets for Western blotting, immunoprecipitation, and kinase assays. This workflow shows how an EDTA-free, DMSO-based formulation can improve sample handling without overlooking assay-specific interference.

• AP1903 for FKBP Dimerization Assays

  2026-09-21

  AP1903 provides a chemically timed switch for F36V-FKBP fusion proteins, supporting controlled protein activation, apoptosis pathway research, and conditional cell ablation. Pairing this FKBP-binding ligand with expression-calibrated transgene libraries can separate protein abundance effects from dimerization-dependent signaling outcomes.

8614 records 1/575 page Next 12345 下5页 Last page